New pill tebapivat aims to boost red blood cells in sickle cell patients

NCT ID NCT06924970

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 25 times

Summary

This study tests a new drug, tebapivat, to see if it can improve anemia in people with sickle cell disease. About 59 adults will receive either tebapivat or a placebo pill. The main goal is to measure increases in hemoglobin and check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Amsterdam Universitair Medisch Centrum, Locatie AMC

    Amsterdam, North Holland, 1105AZ, Netherlands

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611, United States

  • Boston Medical Center & Boston University School of Medicine

    Boston, Massachusetts, 02118, United States

  • CHR de la Citadelle

    Liège, Wallonne, 4000, Belgium

  • CHU Hôpital Henri Mondor

    Créteil, Île-de-France Region, 94010, France

  • CHU Montreal

    Montreal, Quebec, H2X 3E4, Canada

  • Children's Hospital of Michigan

    Detroit, Michigan, 48304, United States

  • Children's National Hospital

    Washington D.C., District of Columbia, 20010, United States

  • Clinique CHC MontLégia

    Liège, Wallonne, 4420, Belgium

  • Emory-Children's Center/ Children's Healthcare of Atlanta: Arthur M. Blank Hospital

    Atlanta, Georgia, 30322, United States

  • Erasmus MC

    Rotterdam, South Holland, 3015 GD, Netherlands

  • Evelina London Children's Hospital, Guy's and St. Thomas' NHS Foundation Trust

    London, SE5 9RS, United Kingdom

  • Fred Hutchinson Cancer Center, University of Washington

    Seattle, Washington, 98195, United States

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Hôpital Edouard Herriot, CHU de Lyon

    Lyon, Auvergne-Rhône-Alpes, 69003, France

  • Icahn School of Medicine at Mt. Sinai

    New York, New York, 10029, United States

  • Institut Universitaire du Cancer de Toulouse - Oncopole

    Toulouse, Midi Pyrenees, 31059, France

  • Kings College Hospital NHS Foundation Trust

    London, SE5 9RS, United Kingdom

  • Lifespan at Rhode Island Hospital

    Providence, Rhode Island, 02903-4923, United States

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia, 20010, United States

  • Montefiore Medical Center

    The Bronx, New York, 10460, United States

  • Prisma Health Cancer Institute - Farris Road

    Greenville, South Carolina, 29605, United States

  • St. James Hospital

    Dublin, Leinster, D08 A978, Ireland

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, 19107, United States

  • UCHealth at University of Colorado Anschutz Medical Campus

    Aurora, Colorado, 80045, United States

  • UConn Health

    Farmington, Connecticut, 06030-0001, United States

  • Universitair Medisch Centrum Utrecht

    Utrecht, 3584 CX, Netherlands

  • University College London

    London, WC1E 6BT, United Kingdom

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Texas Health Science Center of Houston

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.